• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Implementation of the time-to-event continuous reassessment method design in a phase i platform trial testing novel radiotherapy-drug combinations

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    36446040.pdf
    Size:
    220.8Kb
    Format:
    PDF
    Description:
    Identified with Open Access button
    Download
    Authors
    Walker, K.
    Hinsley, S.
    Phillip, R.
    Oughton, J. B.
    Murden, G.
    Chalmers, A. J.
    Faivre-Finn, Corinne
    Greystoke, A.
    Brown, S. R.
    Affiliation
    Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, England
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    Purpose: CONCORDE is the first phase I drug-radiotherapy (RT) combination platform in non-small-cell lung cancer, designed to assess multiple different DNA damage response inhibitors in combination with radical thoracic RT. Time-to-event continuous reassessment method (TiTE-CRM) methodology will inform dose escalation individually for each different DNA damage response inhibitor-RT combination and a randomized calibration arm will aid attribution of toxicities. We report in detail the novel statistical design and implementation of the TiTE-CRM in the CONCORDE trial. Methods: Statistical parameters were calibrated following recommendations by Lee and Cheung. Simulations were performed to assess the operating characteristics of the chosen models and were written using modified code from the R package dfcrm. Results: The results of the simulation work showed that the proposed statistical model setup can answer the research questions under a wide range of potential scenarios. The proposed models work well under varying levels of recruitment and with multiple adaptations to the original methodology. Conclusion: The results demonstrate how TiTE-CRM methodology may be used in practice in a complex dose-finding platform study. We propose that this novel phase I design has potential to overcome some of the logistical barriers that for many years have prevented timely development of novel drug-RT combinations.
    Citation
    Walker K, Hinsley S, Phillip R, Oughton JB, Murden G, Chalmers AJ, et al. Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations-CONCORDE. JCO Precis Oncol. 2022 Nov;6:e2200133. PubMed PMID: 36446040. Epub 2022/11/30. eng.
    Journal
    JCO Precision Oncology
    URI
    http://hdl.handle.net/10541/625879
    DOI
    10.1200/po.22.00133
    PubMed ID
    36446040
    Additional Links
    https://dx.doi.org/10.1200/po.22.00133
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1200/po.22.00133
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples.
    • Authors: van Werkhoven E, Hinsley S, Frangou E, Holmes J, de Haan R, Hawkins M, Brown S, Love SB
    • Issue date: 2020 Jun 22
    • Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib.
    • Authors: de Haan R, van Werkhoven E, van den Heuvel MM, Peulen HMU, Sonke GS, Elkhuizen P, van den Brekel MWM, Tesselaar MET, Vens C, Schellens JHM, van Triest B, Verheij M
    • Issue date: 2019 Sep 10
    • Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.
    • Authors: Polley MY
    • Issue date: 2011 Jul 30
    • GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials.
    • Authors: Dinart D, Fraisse J, Tosi D, Mauguen A, Touraine C, Gourgou S, Le Deley MC, Bellera C, Mollevi C
    • Issue date: 2020 Jun 24
    • A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method.
    • Authors: North B, Kocher HM, Sasieni P
    • Issue date: 2019 Jun 26
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.